It’s not clear whether the TRIPS agreement is what’s getting in the way of vaccine supply, and waiving intellectual property rights may stifle future innovation.
- Professor of Economics, Loughborough University
Why drug maker Mylan’s decision to introduce a half-price version of its EpiPen could be more than a publicity stunt.
What will happen to immigration, wages and the economy has been discussed at length. But the price of drugs may also be affected.
Contact Farasat for
- General
- Media request
- Speaking request
- Consulting / Advising
- Research collaboration
- Research supervision
